Long-Term Risk of Subsequent Neoplasms in 5-Year Survivors of Childhood Neuroblastoma: A Dutch Childhood Cancer Survivor Study-LATER 3 Study
Journal of Clinical Oncology · 2025
DOI: 10.1200/jco.23.01430 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Aimée S R Westerveld und 14 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Neuroblastoma, Cancer Survivors, Neoplasms, Second Primary. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Neuroblastoma survivors have an increased risk of developing subsequent malignant neoplasms (SMNs), but the risk of subsequent nonmalignant neoplasms (SNMNs) and risk factors are largely unknown. We analyzed the long-term risks and associated risk factors for developing SMNs and SNMNs in a well-characterized cohort of 5-year neuroblastoma survivors. METHODS We included 563 5-year neuroblastoma survivors from the Dutch Childhood Cancer Survivor Study (DCCSS)-LATER cohort, diagnosed during 1963-2014. Subsequent neoplasms were ascertained by linkages with the Netherlands Cancer Registry and the Dutch Nationwide Pathology Databank (Palga) and medical chart review. We calculated standardized incidence ratios (SIRs), absolute excess risk (AER), and cumulative incidences. Multivariable competing risk regression analysis was used to evaluate risk factors. RESULTS In total, 23 survivors developed an SMN and 60 an SNMN. After a median follow-up of 23.7 (range, 5.0-56.3) years, the risk of SMN was elevated compared with the general population (SIR, 4.0; 95% CI, 2.5 to 5.9; AER per 10,000 person-years, 15.1). The 30-year cumulative incidence was 3.4% (95% CI, 1.9 to 6.0) for SMNs and 10.4% (95% CI, 7.3 to 14.8) for SNMNs. Six survivors developed an SMN after iodine-metaiodobenzylguanidine ( 131I MIBG) treatment. Survivors treated with 131I MIBG had a higher risk of developing SMNs (subdistribution hazard ratio [SHR], 5.7; 95% CI, 1.8 to 17.8) and SNMNs (SHR, 2.6; 95% CI, 1.2 to 5.6) compared with survivors treated without 131I MIBG; results for SMNs were attenuated in high-risk patients only (SMNs SHR, 3.6; 95% CI, 0.9 to 15.3; SNMNs SHR, 1.5; 95% CI, 0.7 to 3.6). CONCLUSION Our results demonstrate that neuroblastoma survivors have an elevated risk of developing SMNs and a high risk of SNMNs. 131I MIBG may be a treatment-related risk factor for the development of SMN and SNMN, which needs further validation. Our results emphasize the need for awareness of subsequent neoplasms and the importance of follow-up care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
- Department of Pediatric Endocrinology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, the Netherlands.
- Department of Imaging & Cancer, University Medical Center Utrecht, Utrecht, the Netherlands.
- Department of Hematology, Radboudumc Center of Expertise for Cancer Survivorship, Radboud University Medical Center, Nijmegen, the Netherlands.
- Netherlands Department of Pediatric Oncology/Hematology, Erasmus Medical Center, Rotterdam, the Netherlands.
- Department of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands.
ORCID-Profile: Aimée S R Westerveld, Godelieve A M Tytgat, Hanneke M van Santen, Max M van Noesel, Jacqueline Loonen, Andrica C H de Vries, Margriet van der Heiden-van der Loo, Ronald R de Krijger, Cecile M Ronckers, Helena J H van der Pal, Jop C Teepen
Zitieren
APA
Westerveld, A. S. R., Tytgat, G. A. M., van Santen, H. M., van Noesel, M. M., Loonen, J., de Vries, A. C. H., Louwerens, M., Koopman, M. M. W., van der Heiden-van der Loo, M., Janssens, G. O., de Krijger, R. R., Ronckers, C. M., van der Pal, H. J. H., Kremer, L. C. M., & Teepen, J. C. (2025). Long-Term Risk of Subsequent Neoplasms in 5-Year Survivors of Childhood Neuroblastoma: A Dutch Childhood Cancer Survivor Study-LATER 3 Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01430
Vancouver
Westerveld ASR, Tytgat GAM, van Santen HM, van Noesel MM, Loonen J, de Vries ACH, et al. Long-Term Risk of Subsequent Neoplasms in 5-Year Survivors of Childhood Neuroblastoma: A Dutch Childhood Cancer Survivor Study-LATER 3 Study. Journal of Clinical Oncology. 2025. doi:10.1200/jco.23.01430
BibTeX
@article{Westerveld2025,
author = {Westerveld, Aimée S R and Tytgat, Godelieve A M and van Santen, Hanneke M and van Noesel, Max M and Loonen, Jacqueline and de Vries, Andrica C H and Louwerens, Marloes and Koopman, Maria M W and van der Heiden-van der Loo, Margriet and Janssens, Geert O and de Krijger, Ronald R and Ronckers, Cecile M and van der Pal, Helena J H and Kremer, Leontien C M and Teepen, Jop C},
title = {Long-Term Risk of Subsequent Neoplasms in 5-Year Survivors of Childhood Neuroblastoma: A Dutch Childhood Cancer Survivor Study-LATER 3 Study},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco.23.01430}
}
EUVIMED